The North Midlands Clinical Research Delivery Centre (CRDC) has recruited its first patient, representing the UK’s initial participation in a clinical trial of DM199 focused on improving outcomes for acute ischaemic stroke patients.
The North Midlands CRDC is based at the University Hospitals of North Midlands NHS Trust (UHNM).
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Being conducted at Royal Stoke University Hospital in collaboration with UHNM’s stroke service and research and innovation teams, the ReMEDy2 global study is assessing the therapy for patients who have experienced an acute ischaemic stroke.
These patients are not eligible for standard clot-busting therapies within the advised timeframe.
It investigates whether DM199 can be administered up to 24 hours after the onset of symptoms, potentially expanding access to treatment.
UHNM principal investigator and consultant acute stroke physician Christine Roffe said: “For many stroke patients, treatment options are limited by time, as standard clot-busting drugs must be given within hours of symptom onset. Patients who arrive outside this window often have no further treatment available.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataLynn Doherty, a 65-year-old woman from Bradley, became the North Midlands CRDC’s first patient recruited after experiencing a stroke at work in January 2026, and was also the first UK participant in the ReMEDy2 trial.
Doherty said: “Saying yes to the trial was about helping people in the future who might benefit from this treatment. If it becomes a standard therapy one day, it could make a real difference. You also get extra monitoring and support, but my main reason was to help others.”
The North Midlands CRDC received £3.1m ($4.3m) in government funding as part of a UK-wide initiative involving 21 CRDCs focused on enhancing NHS research delivery and health outcomes.
